BofA raised the firm’s price target on Addus HomeCare to $118 from $115 and keeps a Buy rating on the shares after the company reported adjusted EBITDA 11% above consensus and adjusted EPS that was 10% above consensus estimates. The firm raised its EBITDA estimates for the beat, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Addus Homecare Releases Quarterly Financial Results
- Addus HomeCare Corporation (ADUS) Q1 Earnings Cheat Sheet
- Roblox upgraded, Qualcomm initiated: Wall Street’s top analyst calls
- Barclays downgrades Addus to Underweight on ‘materially negative’ regulation
- Addus HomeCare falls 4% after HHS announced Medicaid Services rule
